MannKind Corporation
MNKD
Positions held
Your positionsMNKD isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- MannKind Corporation is positioned well in the biotechnology sector, focusing on innovative treatments for diabetes, which is a growing market due to rising global prevalence.
- Revenue increased by 21% compared to the prior quarter, reaching $109 million.
- The company's gross margin remains strong at 73%, despite a slight decrease from the previous quarter.
- MannKind faces significant challenges with a negative profit margin of -11.08%, indicating ongoing financial struggles.
- The operating margin has been negative, with a recent quarterly figure of -0.8%.
- The stock has a price-to-book ratio of -17.1, suggesting potential overvaluation concerns.
Fundamentals
| Market cap | $1.10B | Enterprise value | $1.42B | Trailing P/E | — | Forward P/E | 26.82 |
| PEG | 4.39 | Price / book | -15.76 | Beta | 1.08 | Dividend yield | 0.00% |
| Revenue growth | 42.9% | Earnings growth | — | Gross margin | 75.4% | Operating margin | -0.8% |
| Profit margin | -11.1% | ROE | — | ROA | 0.8% | Debt / equity | — |
| Current ratio | 1.72 | Free cash flow | $40.31M | Analyst recommendation | strong_buy | Mean target | $7.84 |
| 52w high | $6.51 | 52w low | $2.23 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $109M | $90.2M | $112M | $82.1M | $76.5M | — |
| Op margin | -0.8% | -3.3% | -6.9% | 22.9% | 13.9% | — |
| Net income | -$19.0M | -$16.6M | -$15.9M | $8.0M | $0.7M | — |
| Gross margin | 73.0% | 80.6% | 73.5% | 75.4% | 73.1% | — |
| Gross profit | $79.8M | $72.7M | $82.3M | $61.9M | $56.0M | — |
| Operating income | -$0.8M | -$3.0M | -$7.7M | $18.8M | $10.7M | — |
- Revenue +21% vs prior quarter ($109M vs $90M).
- Gross margin 73% (was 80.6% prior quarter).
- Operating margin expanded to -0.8%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $349M | $286M | $199M | $99.8M | — |
| Op margin | 13.3% | 24.1% | 5.3% | -69.1% | — |
| Net income | $5.9M | $27.6M | -$11.9M | -$87.4M | — |
| Gross margin | 74.8% | 73.2% | 68.5% | 42.4% | — |
| Gross profit | $261M | $209M | $136M | $42.3M | — |
| Operating income | $46.5M | $68.7M | $10.6M | -$68.9M | — |
Headlines — positive tone
• [OK · fundamentals] MannKind Corp (MNKD) (Q2 2026) Earnings Call Highlights: Record Revenue and Major Catalysts ...
News
2026-09-17 · MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum
2026-09-16 · MannKind (MNKD) Bets On Inhaled Weight Loss Amid Widening Losses
2026-09-09 · MannKind Expands Into Weight Loss With Rose Pharma Deal – Here’s What Investors Are Watching
2026-09-09 · MannKind, Rose Pharma Sign Deal to Develop Weight-Management Drug
2026-09-02 · MannKind to Present at Upcoming Investor Conferences
2026-08-29 · MannKind (MNKD) Could Be 48% Undervalued Following Its Afrezza And Pipeline Narrative
2026-08-28 · FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH
2026-08-06 · MannKind's Diversified Portfolio Seen Leading to Higher Revenue in H2, Wedbush Says
2026-08-06 · MannKind Corp (MNKD) (Q2 2026) Earnings Call Highlights: Record Revenue and Major Catalysts ...
2026-08-06 · MannKind Q2 Earnings Call Highlights
2026-08-05 · Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics
Price (daily)
Full chart · RSI · MACD · patterns